DuPont Reports Fourth-Quarter and Full-Year Results
Fourth-Quarter Highlights |
|
Full-Year Highlights |
|
1 |
Generally Accepted Accounting Principles (GAAP) |
2 |
See schedules A, C, and D for definitions and reconciliations of non-GAAP measures. |
3 |
GAAP operating costs defined as other operating charges, selling, general & administrative, and research & development costs. |
4 |
Free cash flow is defined as cash used for operating activities less purchases of property, plant and equipment. See schedule A for reconciliation of non-GAAP measure. |
E. |
For the full-year 2016,
Fourth-quarter sales were
Free cash flow4 improvement of
"2016 was an important year for
Global Consolidated
Three Months Ended |
||||||||||||
|
Percent Change Due to: |
|||||||||||
% |
Local Price and |
Portfolio / |
||||||||||
$ |
Change |
Product Mix |
Currency |
Volume |
Other |
|||||||
(Dollars in millions) |
||||||||||||
|
$ 1,676 |
(11) |
(7) |
- |
(4) |
- |
||||||
EMEA * |
1,183 |
(1) |
- |
(1) |
- |
- |
||||||
Asia Pacific |
1,543 |
9 |
- |
1 |
9 |
(1) |
||||||
|
809 |
- |
2 |
7 |
(9) |
- |
||||||
Total Consolidated Sales |
$ 5,211 |
(2) |
(2) |
1 |
(1) |
- |
||||||
Twelve Months Ended |
||||||||||||
|
Percent Change Due to: |
|||||||||||
% |
Local Price and |
Portfolio / |
||||||||||
$ |
Change |
Product Mix |
Currency |
Volume |
Other |
|||||||
(Dollars in millions) |
||||||||||||
|
$ 10,413 |
(3) |
(2) |
- |
- |
(1) |
||||||
EMEA * |
5,739 |
(5) |
1 |
(3) |
(2) |
(1) |
||||||
Asia Pacific |
5,801 |
3 |
(1) |
(1) |
4 |
1 |
||||||
|
2,641 |
(3) |
2 |
(2) |
(2) |
(1) |
||||||
Total Consolidated Sales |
$ 24,594 |
(2) |
(1) |
(1) |
- |
- |
||||||
* |
Segment
Three Months Ended |
||||||||||||
|
Percent Change Due to: |
|||||||||||
Local Price and |
Portfolio / |
|||||||||||
$ |
% Change |
Product Mix |
Currency |
Volume |
Other |
|||||||
(Dollars in millions) |
||||||||||||
Agriculture |
$ 1,393 |
(10) |
(4) |
4 |
(9) |
(1) |
||||||
|
521 |
6 |
- |
- |
6 |
- |
||||||
Industrial Biosciences |
401 |
1 |
(1) |
(1) |
2 |
1 |
||||||
Nutrition & Health |
809 |
- |
- |
- |
- |
- |
||||||
Performance Materials |
1,331 |
4 |
(2) |
- |
7 |
(1) |
||||||
Protection Solutions |
717 |
- |
- |
- |
- |
- |
||||||
Other |
39 |
|||||||||||
Consolidated |
5,211 |
(2) |
(2) |
1 |
(1) |
- |
Segment
Twelve Months Ended |
||||||||||||
|
Percent Change Due to: |
|||||||||||
Local Price and |
Portfolio / |
|||||||||||
$ |
% Change |
Product Mix |
Currency |
Volume |
Other |
|||||||
(Dollars in millions) |
||||||||||||
Agriculture |
$ 9,516 |
(3) |
- |
(2) |
(1) |
- |
||||||
|
1,960 |
(5) |
(2) |
- |
(3) |
- |
||||||
Industrial Biosciences |
1,500 |
1 |
- |
(2) |
2 |
1 |
||||||
Nutrition & Health |
3,268 |
- |
- |
(2) |
2 |
- |
||||||
Performance Materials |
5,249 |
(1) |
(3) |
(1) |
3 |
- |
||||||
Protection Solutions |
2,954 |
(3) |
(1) |
- |
(2) |
- |
||||||
Other |
147 |
|||||||||||
Consolidated |
24,594 |
(2) |
(1) |
(1) |
- |
- |
Operating Earnings – 4th Quarter and Full Year
Change vs. 2015 |
|||||||
(Dollars in millions) |
4Q16 |
4Q15 |
$ |
% |
|||
Agriculture |
$ (19) |
$ (54) |
$ 35 |
65% |
|||
|
98 |
87 |
11 |
13% |
|||
Industrial Biosciences |
67 |
78 |
(11) |
-14% |
|||
Nutrition & Health |
135 |
85 |
50 |
59% |
|||
Performance Materials |
328 |
281 |
47 |
17% |
|||
Protection Solutions |
142 |
147 |
(5) |
-3% |
|||
Other |
(48) |
(71) |
23 |
32% |
|||
Total segment operating earnings (5) |
703 |
553 |
150 |
27% |
|||
Exchange gains (losses) (6) |
106 |
(24) |
130 |
nm |
|||
Corporate expenses (5) |
(88) |
(160) |
72 |
-45% |
|||
Interest expense |
(92) |
(82) |
(10) |
12% |
|||
Operating earnings before income taxes (2) |
629 |
287 |
342 |
119% |
|||
Provision for income taxes on operating earnings (2) |
(180) |
(51) |
(129) |
||||
Less: Net income attributable to noncontrolling interests |
(2) |
(3) |
1 |
||||
Operating earnings (2) |
$ 451 |
$ 239 |
$ 212 |
89% |
|||
Operating earnings per share (2) |
|
$ 0.27 |
$ 0.24 |
89% |
|||
GAAP earnings per share |
|
$ (0.26) |
$ 0.55 |
212% |
Operating Earnings – 4th Quarter and Full Year, Continued
Change vs. 2015 |
|||||||
(Dollars in millions) |
YTD 2016 |
YTD 2015 |
$ |
% |
|||
Agriculture |
$ 1,758 |
$ 1,646 |
$ 112 |
7% |
|||
|
358 |
359 |
(1) |
0% |
|||
Industrial Biosciences |
270 |
243 |
27 |
11% |
|||
Nutrition & Health |
504 |
373 |
131 |
35% |
|||
Performance Materials |
1,297 |
1,216 |
81 |
7% |
|||
Protection Solutions |
668 |
641 |
27 |
4% |
|||
Other |
(215) |
(235) |
20 |
9% |
|||
Total segment operating earnings (5) |
4,640 |
4,243 |
397 |
9% |
|||
Exchange gains (losses) (5) (6) |
(106) |
93 |
(199) |
nm |
|||
Corporate expenses (5) |
(340) |
(573) |
233 |
-41% |
|||
Interest expense |
(370) |
(322) |
(48) |
15% |
|||
Operating earnings before income taxes (2) |
3,824 |
3,441 |
383 |
11% |
|||
Provision for income taxes on operating earnings (2) |
(861) |
(932) |
71 |
||||
Less: Net income attributable to noncontrolling interests |
12 |
6 |
6 |
||||
Operating earnings (2) |
$ 2,951 |
$ 2,503 |
$ 448 |
18% |
|||
Operating earnings per share (2) |
|
$ 2.77 |
$ 0.58 |
21% |
|||
GAAP earnings per share |
|
$ 2.09 |
$ 0.76 |
36% |
|||
(5) See Schedules B and C for listing of significant items. |
|||||||
(6) See Schedule D for additional information on exchange gains and losses. |
The following is a summary of business results for each of the company's reportable segments comparing fourth quarter and full year with the prior year, unless otherwise noted.
Agriculture – For the fourth-quarter 2016, an operating loss of
Full-year operating earnings of
Electronics & Communications – Fourth-quarter 2016 operating earnings of
Full-year operating earnings of
Industrial Biosciences - Fourth-quarter 2016 operating earnings of
Full-year operating earnings of
Nutrition & Health – Fourth-quarter 2016 operating earnings of
Full-year operating earnings of
Performance Materials - Fourth-quarter 2016 operating earnings of
Full-year operating earnings of
Protection Solutions – Fourth-quarter 2016 operating earnings of
Full-year operating earnings of
First-Quarter 2017 Outlook
We expect the merger to close in the first half of 2017, pending regulatory approval. Therefore, only guidance for the first quarter of 2017 is being provided. The company expects first-quarter 2017 GAAP earnings to decrease about 18 percent from prior year. The company's first-quarter 2017 GAAP earnings include an expected charge of about
First-quarter 2017 operating earnings2 are expected to increase about 8 percent versus prior year driven by benefits from cost savings and the impact of the change in timing for seed deliveries, primarily related to the southern
Use of Non-GAAP Measures
This earnings release includes information that does not conform to
About
Forward-Looking Statements: This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words.
Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company's control. Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company's intellectual property rights; successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses; and risks related to the agreement entered on
Consolidated Income Statements (Dollars in millions, except per share amounts) |
|||||||||||||||
SCHEDULE A |
|||||||||||||||
Three Months Ended |
Twelve Months Ended |
||||||||||||||
2016 |
2015 |
2016 |
2015 |
||||||||||||
Net sales |
$ |
5,211 |
$ |
5,299 |
$ |
24,594 |
$ |
25,130 |
|||||||
Cost of goods sold |
3,147 |
3,409 |
14,469 |
15,112 |
|||||||||||
Other operating charges (1) |
182 |
46 |
686 |
459 |
|||||||||||
Selling, general and administrative expenses (1) |
964 |
1,075 |
4,319 |
4,615 |
|||||||||||
Research and development expense |
381 |
483 |
1,641 |
1,898 |
|||||||||||
Other income, net (1) |
(301) |
(145) |
(708) |
(697) |
|||||||||||
Interest expense (1) |
92 |
82 |
370 |
342 |
|||||||||||
Employee separation / asset related charges, net (1) |
393 |
770 |
552 |
810 |
|||||||||||
Income (loss) from continuing operations before income taxes |
353 |
(421) |
3,265 |
2,591 |
|||||||||||
Provision for (benefit from) income taxes on continuing operations (1) |
101 |
(190) |
744 |
696 |
|||||||||||
Income (loss) from continuing operations after income taxes |
252 |
(231) |
2,521 |
1,895 |
|||||||||||
Income (loss) from discontinued operations after income taxes |
11 |
(25) |
4 |
64 |
|||||||||||
Net income (loss) |
263 |
(256) |
2,525 |
1,959 |
|||||||||||
Less: Net (loss) income attributable to noncontrolling interests |
(2) |
(3) |
12 |
6 |
|||||||||||
Net income (loss) attributable to |
$ |
265 |
$ |
(253) |
$ |
2,513 |
$ |
1,953 |
|||||||
Basic earnings (loss) per share of common stock: |
|||||||||||||||
Basic earnings (loss) per share of common stock from continuing operations |
$ |
0.29 |
$ |
(0.26) |
$ |
2.86 |
$ |
2.10 |
|||||||
Basic earnings (loss) per share of common stock from discontinued operations |
0.01 |
(0.03) |
— |
0.07 |
|||||||||||
Basic earnings (loss) per share of common stock (2) |
$ |
0.30 |
$ |
(0.29) |
$ |
2.87 |
$ |
2.17 |
|||||||
Diluted earnings (loss) per share of common stock: |
|||||||||||||||
Diluted earnings (loss) per share of common stock from continuing operations |
$ |
0.29 |
$ |
(0.26) |
$ |
2.85 |
$ |
2.09 |
|||||||
Diluted earnings (loss) per share of common stock from discontinued operations |
0.01 |
(0.03) |
— |
0.07 |
|||||||||||
Diluted earnings (loss) per share of common stock (2) |
$ |
0.30 |
$ |
(0.29) |
$ |
2.85 |
$ |
2.16 |
|||||||
Dividends per share of common stock |
$ |
0.38 |
$ |
0.38 |
$ |
1.52 |
$ |
1.72 |
|||||||
Average number of shares outstanding used in earnings (loss) per share (EPS) calculation: |
|||||||||||||||
Basic |
867,460,000 |
876,500,000 |
872,560,000 |
893,992,000 |
|||||||||||
Diluted |
872,363,000 |
881,727,000 |
877,036,000 |
899,527,000 |
|||||||||||
Reconciliation of Non-GAAP Measures |
|||||||||||||||||||||
Summary of Earnings Comparison |
|||||||||||||||||||||
Three Months Ended |
Twelve Months Ended |
||||||||||||||||||||
2016 |
2015 |
% Change |
2016 |
2015 |
% Change |
||||||||||||||||
Income (loss) from continuing operations after income taxes (GAAP) |
$ |
252 |
$ |
(231) |
209%
|
$ |
2,521 |
$ |
1,895 |
33%
|
|||||||||||
Less: Significant items charge included in income from continuing operations |
(384) |
(411) |
(421) |
(348) |
|||||||||||||||||
Non-operating pension/OPEB benefits (costs) included in income from |
187 |
(56) |
(21) |
(266) |
|||||||||||||||||
Net (loss) income attributable to noncontrolling interest from continuing |
(2) |
(3) |
12 |
6 |
|||||||||||||||||
Operating earnings (Non-GAAP) (4) |
$ |
451 |
$ |
239 |
89%
|
$ |
2,951 |
$ |
2,503 |
18%
|
|||||||||||
Earnings (loss) per share from continuing operations (GAAP) |
$ |
0.29 |
$ |
(0.26) |
212%
|
$ |
2.85 |
$ |
2.09 |
36%
|
|||||||||||
Less: Significant items charge included in EPS (per Schedule B) |
(0.44) |
(0.47) |
(0.48) |
(0.39) |
|||||||||||||||||
Non-operating pension/OPEB benefits (costs) included in EPS (3) |
0.22 |
(0.06) |
(0.02) |
(0.29) |
|||||||||||||||||
Operating earnings per share (Non-GAAP) (4) |
$ |
0.51 |
$ |
0.27 |
89%
|
$ |
3.35 |
$ |
2.77 |
21%
|
|||||||||||
Condensed Consolidated Balance Sheets (Dollars in millions, except per share amounts) |
||||||||
SCHEDULE A (continued) |
||||||||
2016 |
2015 |
|||||||
Assets |
||||||||
Current assets |
||||||||
Cash and cash equivalents |
$ |
4,605 |
$ |
5,300 |
||||
Marketable securities |
1,362 |
906 |
||||||
Accounts and notes receivable, net |
4,971 |
4,643 |
||||||
Inventories |
5,673 |
6,140 |
||||||
Prepaid expenses |
506 |
398 |
||||||
Total current assets |
17,117 |
17,387 |
||||||
Property, plant and equipment, net of accumulated depreciation ( |
9,231 |
9,784 |
||||||
|
4,180 |
4,248 |
||||||
Other intangible assets |
3,664 |
4,144 |
||||||
Investment in affiliates |
649 |
688 |
||||||
Deferred income taxes |
3,308 |
3,799 |
||||||
Other assets |
1,815 |
1,116 |
||||||
Total |
$ |
39,964 |
$ |
41,166 |
||||
Liabilities and Equity |
||||||||
Current liabilities |
||||||||
Accounts payable |
$ |
3,705 |
$ |
3,398 |
||||
Short-term borrowings and capital lease obligations |
429 |
1,165 |
||||||
Income taxes |
101 |
173 |
||||||
Other accrued liabilities |
4,662 |
5,580 |
||||||
Total current liabilities |
8,897 |
10,316 |
||||||
Long-term borrowings and capital lease obligations |
8,107 |
7,642 |
||||||
Other liabilities |
12,333 |
12,591 |
||||||
Deferred income taxes |
431 |
417 |
||||||
Total liabilities |
29,768 |
30,966 |
||||||
Commitments and contingent liabilities |
||||||||
Stockholders' equity |
||||||||
Preferred stock |
237 |
237 |
||||||
Common stock, Issued at |
285 |
288 |
||||||
Additional paid-in capital |
11,190 |
11,081 |
||||||
Reinvested earnings |
14,924 |
14,510 |
||||||
Accumulated other comprehensive loss |
(9,911) |
(9,396) |
||||||
Common stock held in treasury, at cost (87,041,000 shares at |
(6,727) |
(6,727) |
||||||
Total |
9,998 |
9,993 |
||||||
Noncontrolling interests |
198 |
207 |
||||||
Total equity |
10,196 |
10,200 |
||||||
Total |
$ |
39,964 |
$ |
41,166 |
Condensed Consolidated Statement of Cash Flows (Dollars in millions) |
|||||||
SCHEDULE A (continued) |
|||||||
Twelve Months Ended |
|||||||
2016 |
2015 |
||||||
|
|||||||
Net income |
$ |
2,525 |
$ |
1,959 |
|||
Adjustments to reconcile net income to cash provided by operating activities: |
|||||||
Depreciation |
939 |
1,104 |
|||||
Amortization of intangible assets |
319 |
362 |
|||||
Net periodic pension benefit cost |
572 |
591 |
|||||
Contributions to pension plans |
(535) |
(308) |
|||||
Gain on sale of businesses and other assets |
(436) |
(59) |
|||||
Asset-related charges |
682 |
147 |
|||||
Other operating activities - net |
366 |
106 |
|||||
Change in operating assets and liabilities - net |
(1,132) |
(1,586) |
|||||
Cash provided by operating activities |
3,300 |
2,316 |
|||||
Investing activities |
|||||||
Purchases of property, plant and equipment |
(1,019) |
(1,629) |
|||||
Investments in affiliates |
(19) |
(76) |
|||||
Payments for businesses - net of cash acquired |
— |
(152) |
|||||
Proceeds from sale of businesses and other assets - net |
316 |
156 |
|||||
Net increase in short-term financial instruments |
(452) |
(776) |
|||||
Foreign currency exchange contract settlements |
(385) |
615 |
|||||
Other investing activities - net |
45 |
34 |
|||||
Cash used for investing activities |
(1,514) |
(1,828) |
|||||
Financing activities |
|||||||
Dividends paid to stockholders |
(1,335) |
(1,546) |
|||||
Net (decrease) increase in borrowings |
(240) |
2,141 |
|||||
Repurchase of common stock |
(916) |
(2,353) |
|||||
Proceeds from exercise of stock options |
181 |
274 |
|||||
Cash transferred to Chemours at spin-off |
— |
(250) |
|||||
Other financing activities - net |
(18) |
(89) |
|||||
Cash used for financing activities |
(2,328) |
(1,823) |
|||||
Effect of exchange rate changes on cash |
(153) |
(275) |
|||||
Decrease in cash and cash equivalents |
(695) |
(1,610) |
|||||
Cash and cash equivalents at beginning of period |
5,300 |
6,910 |
|||||
Cash and cash equivalents at end of period |
$ |
4,605 |
$ |
5,300 |
|||
Reconciliation of Non-GAAP Measure |
|||||||
Calculation of Free Cash Flow - |
|||||||
Twelve Months Ended |
|||||||
2016 |
2015 |
||||||
Cash provided by operating activities (GAAP) |
$ |
3,300 |
$ |
2,316 |
|||
Purchases of property, plant and equipment |
(1,019) |
(1,629) |
|||||
Free cash flow (Non-GAAP) |
$ |
2,281 |
$ |
687 |
|||
(1) |
See Schedule B for detail of significant items. |
|||||||
(2) |
The sum of the individual earnings per share amounts from continuing operations and discontinued operations may not equal the total company earnings per share amounts due to rounding. |
|||||||
(3) |
Fourth quarter 2016 and year to date 2016, non-operating pension/OPEB benefits / (costs) include a |
|||||||
(4) |
Operating earnings and operating earnings per share are defined as earnings from continuing operations excluding significant items and non-operating pension/OPEB costs. Non-operating pension/OPEB costs includes all of the components of net periodic benefit cost from continuing operations with the exception of the service cost component. |
Schedule of Significant Items from Continuing Operations (Dollars in millions, except per share amounts) |
||||||||||||||||||||||||
SCHEDULE B |
||||||||||||||||||||||||
SIGNIFICANT ITEMS |
||||||||||||||||||||||||
Pre-tax |
After-tax(8) |
($ Per Share) |
||||||||||||||||||||||
2016 |
2015 |
2016 |
2015 |
2016 |
2015 |
|||||||||||||||||||
1st Quarter |
||||||||||||||||||||||||
Transaction costs(1) |
$ |
(24) |
$ |
(12) |
$ |
(21) |
$ |
(11) |
$ |
(0.02) |
$ |
(0.01) |
||||||||||||
Customer claims adjustment/recovery(4) |
23 |
35 |
15 |
22 |
0.02 |
0.02 |
||||||||||||||||||
Gain on sale of entity(5) |
369 |
— |
214 |
— |
0.24 |
— |
||||||||||||||||||
Restructuring charges, net(2) |
(77) |
— |
(48) |
— |
(0.06) |
— |
||||||||||||||||||
Asset impairment charge(3) |
— |
(37) |
— |
(30) |
— |
(0.03) |
||||||||||||||||||
|
— |
(40) |
— |
(38) |
— |
(0.04) |
||||||||||||||||||
1st Quarter - Total |
$ |
291 |
$ |
(54) |
$ |
160 |
$ |
(57) |
$ |
0.18 |
$ |
(0.06) |
||||||||||||
2nd Quarter |
||||||||||||||||||||||||
Transaction costs(1) |
$ |
(76) |
$ |
(25) |
$ |
(59) |
$ |
(38) |
$ |
(0.07) |
$ |
(0.04) |
||||||||||||
Customer claims recovery(4) |
30 |
— |
19 |
— |
0.02 |
— |
||||||||||||||||||
Restructuring adjustments / charges(2) |
90 |
(2) |
59 |
(2) |
0.07 |
— |
||||||||||||||||||
Litigation settlement(7) |
— |
112 |
— |
72 |
— |
0.08 |
||||||||||||||||||
2nd Quarter - Total |
$ |
44 |
$ |
85 |
$ |
19 |
$ |
32 |
$ |
0.02 |
$ |
0.04 |
||||||||||||
3rd Quarter |
||||||||||||||||||||||||
Transaction costs(1) |
$ |
(122) |
$ |
(9) |
$ |
(91) |
$ |
(6) |
$ |
(0.10) |
$ |
(0.01) |
||||||||||||
Restructuring charges, net(2) |
(17) |
— |
(14) |
— |
(0.02) |
— |
||||||||||||||||||
Asset impairment charge(3) |
(158) |
— |
(111) |
— |
(0.13) |
— |
||||||||||||||||||
Customer claims adjustment/recovery(4) |
— |
147 |
— |
94 |
— |
0.11 |
||||||||||||||||||
3rd Quarter - Total |
$ |
(297) |
$ |
138 |
$ |
(216) |
$ |
88 |
$ |
(0.25) |
$ |
0.10 |
||||||||||||
4th Quarter |
||||||||||||||||||||||||
Transaction costs(1) |
$ |
(164) |
$ |
(10) |
$ |
(131) |
$ |
(7) |
$ |
(0.15) |
$ |
(0.01) |
||||||||||||
Restructuring adjustments / charges(2) |
42 |
(775) |
25 |
(508) |
0.03 |
(0.58) |
||||||||||||||||||
Asset impairment charge(3) |
(435) |
— |
(278) |
— |
(0.32) |
— |
||||||||||||||||||
Litigation settlement (7) |
— |
33 |
— |
21 |
— |
0.02 |
||||||||||||||||||
Customer claims adjustment/recovery (4) |
— |
130 |
— |
83 |
— |
0.10 |
||||||||||||||||||
4th Quarter - Total |
$ |
(557) |
$ |
(622) |
$ |
(384) |
$ |
(411) |
$ |
(0.44) |
$ |
(0.47) |
||||||||||||
Year-to-date Total (9) |
$ |
(519) |
$ |
(453) |
$ |
(421) |
$ |
(348) |
$ |
(0.48) |
$ |
(0.39) |
Schedule of Significant Items from Continuing Operations (Dollars in millions, except per share amounts) |
|
(1) |
Fourth, third, second, and first quarter 2016 included charges of
|
Third quarter and first quarter 2015 included charges of |
|
(2) |
Fourth, third, second and first quarter 2016 included benefits / (charges) of
|
Fourth quarter 2015 included a
|
|
Fourth quarter 2016 included a benefit of
|
|
Fourth quarter 2016 and fourth quarter 2015 included benefits of
|
|
(3) |
During the fourth quarter 2016, a
|
During third quarter 2016, a
|
|
During first quarter 2015, a $(37) pre-tax impairment charge was recorded in employee separation / asset related charges, net for a cost basis investment within the Other segment. The assessment resulted from the venture's revised operating plan reflecting underperformance of its European wheat based ethanol facility and deteriorating European ethanol market conditions. |
|
(4) |
In the second quarter 2016, third quarter 2015 and first quarter 2015, the company recorded insurance recoveries of
|
(5) |
First quarter 2016 included a gain of |
(6) |
First quarter 2015 included a charge of |
(7) |
Fourth and second quarter 2015 included gains of |
(8) |
Unless specifically addressed in notes above, the income tax effect on significant items is calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. |
(9) |
Earnings per share for the year may not equal the sum of quarterly earnings per share due to the changes in average share calculations. |
Consolidated Segment Information (Dollars in millions) |
||||||||||||||||
SCHEDULE C |
||||||||||||||||
Three Months Ended |
Twelve Months Ended |
|||||||||||||||
SEGMENT |
2016 |
2015 |
2016 |
2015 |
||||||||||||
Agriculture |
$ |
1,393 |
$ |
1,550 |
$ |
9,516 |
$ |
9,798 |
||||||||
|
521 |
493 |
1,960 |
2,070 |
||||||||||||
Industrial Biosciences |
401 |
397 |
1,500 |
1,478 |
||||||||||||
Nutrition & Health |
809 |
807 |
3,268 |
3,256 |
||||||||||||
Performance Materials |
1,331 |
1,284 |
5,249 |
5,305 |
||||||||||||
Protection Solutions |
717 |
720 |
2,954 |
3,039 |
||||||||||||
Other |
39 |
48 |
147 |
184 |
||||||||||||
Consolidated net sales |
$ |
5,211 |
$ |
5,299 |
$ |
24,594 |
$ |
25,130 |
||||||||
Three Months Ended |
Twelve Months Ended |
|||||||||||||||
SEGMENT OPERATING EARNINGS (1) |
2016 |
2015 |
2016 |
2015 |
||||||||||||
Agriculture |
$ |
(19) |
$ |
(54) |
$ |
1,758 |
$ |
1,646 |
||||||||
|
98 |
87 |
358 |
359 |
||||||||||||
Industrial Biosciences |
67 |
78 |
270 |
243 |
||||||||||||
Nutrition & Health |
135 |
85 |
504 |
373 |
||||||||||||
Performance Materials |
328 |
281 |
1,297 |
1,216 |
||||||||||||
Protection Solutions |
142 |
147 |
668 |
641 |
||||||||||||
Other |
(48) |
(71) |
(215) |
(235) |
||||||||||||
Total segment operating earnings |
703 |
553 |
4,640 |
4,243 |
||||||||||||
Corporate expenses |
(88) |
(160) |
(340) |
(573) |
||||||||||||
Interest expense |
(92) |
(82) |
(370) |
(322) |
||||||||||||
Operating earnings before income taxes and exchange gains (losses) |
523 |
311 |
3,930 |
3,348 |
||||||||||||
Net exchange gains (losses)(2) |
106 |
(24) |
(106) |
93 |
||||||||||||
Operating earnings before income taxes (Non-GAAP) |
$ |
629 |
$ |
287 |
$ |
3,824 |
$ |
3,441 |
||||||||
Non-operating pension/OPEB benefits (costs) (3) |
281 |
(86) |
(40) |
(397) |
||||||||||||
Total significant items before income taxes |
(557) |
(622) |
(519) |
(453) |
||||||||||||
Income (loss) from continuing operations before income taxes (GAAP) |
$ |
353 |
$ |
(421) |
$ |
3,265 |
$ |
2,591 |
||||||||
Three Months Ended |
Twelve Months Ended |
|||||||||||||||
SIGNIFICANT ITEMS BY SEGMENT (PRE-TAX) (1)(4) |
2016 |
2015 |
2016 |
2015 |
||||||||||||
Agriculture |
$ |
14 |
$ |
(30) |
$ |
(37) |
$ |
148 |
||||||||
|
(9) |
(89) |
4 |
(78) |
||||||||||||
Industrial Biosciences |
2 |
(60) |
(152) |
(61) |
||||||||||||
Nutrition & Health |
(3) |
(46) |
9 |
(50) |
||||||||||||
Performance Materials |
(2) |
(60) |
5 |
(62) |
||||||||||||
Protection Solutions |
4 |
(8) |
14 |
105 |
||||||||||||
Other |
(8) |
— |
(11) |
(40) |
||||||||||||
Total significant items by segment |
(2) |
(293) |
(168) |
(38) |
||||||||||||
Corporate expenses |
(555) |
(329) |
(351) |
(355) |
||||||||||||
Interest expense |
— |
— |
— |
(20) |
||||||||||||
Net exchange gains (losses) |
— |
— |
— |
(40) |
||||||||||||
Total significant items before income taxes |
$ |
(557) |
$ |
(622) |
$ |
(519) |
$ |
(453) |
Consolidated Segment Information (Dollars in millions) |
||||||||||||||||
SCHEDULE C (continued) |
||||||||||||||||
Corporate Expenses |
||||||||||||||||
The reconciliation below reflects GAAP corporate expenses excluding significant items. |
||||||||||||||||
Three Months Ended |
Twelve Months Ended |
|||||||||||||||
2016 |
2015 |
2016 |
2015 |
|||||||||||||
Corporate expenses (GAAP) |
$ |
643 |
$ |
489 |
$ |
691 |
$ |
928 |
||||||||
Less: Significant items charge (4) |
555 |
329 |
351 |
355 |
||||||||||||
Corporate expenses (Non-GAAP) |
$ |
88 |
$ |
160 |
$ |
340 |
$ |
573 |
||||||||
(1) |
Segment operating earnings is defined as income (loss) from continuing operations before income taxes excluding significant pre-tax benefits (charges), non-operating pension/OPEB costs, exchange gains (losses), corporate expenses and interest. |
||||||||||||||||
(2) |
See Schedule D for additional information on exchange gains and losses. Year to date 2015 exchange gains, on an operating earnings basis |
||||||||||||||||
(3) |
Fourth quarter 2016 and year to date 2016, non-operating pension/OPEB benefits (costs) include a |
||||||||||||||||
(4) |
See Schedule B for detail of significant items. |
Reconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts) |
|||||||||||||||||
SCHEDULE D |
|||||||||||||||||
Reconciliations of Adjusted EBIT / EBITDA to Consolidated Income Statements |
|||||||||||||||||
Three Months Ended |
Twelve Months Ended |
||||||||||||||||
2016 |
2015 |
2016 |
2015 |
||||||||||||||
Income (loss) from continuing operations after income taxes (GAAP) |
$ |
252 |
$ |
(231) |
$ |
2,521 |
$ |
1,895 |
|||||||||
Add: Provision for (benefit from) for income taxes on continuing operations |
101 |
(190) |
744 |
696 |
|||||||||||||
Income (loss) from continuing operations before income taxes |
$ |
353 |
$ |
(421) |
$ |
3,265 |
$ |
2,591 |
|||||||||
Add: Significant items charge before income taxes(1) |
557 |
622 |
519 |
453 |
|||||||||||||
Add: Non-operating pension/OPEB (benefits) costs (2) |
(281) |
86 |
40 |
397 |
|||||||||||||
Operating earnings before income taxes (Non-GAAP) |
$ |
629 |
$ |
287 |
$ |
3,824 |
$ |
3,441 |
|||||||||
Less: Net (loss) income attributable to noncontrolling interests from continuing |
(2) |
(3) |
12 |
6 |
|||||||||||||
Add: Interest expense (1) |
92 |
82 |
370 |
322 |
|||||||||||||
Adjusted EBIT from operating earnings (Non-GAAP) |
723 |
372 |
4,182 |
3,757 |
|||||||||||||
Add: Depreciation and amortization |
279 |
303 |
1,258 |
1,338 |
|||||||||||||
Adjusted EBITDA from operating earnings (Non-GAAP) |
$ |
1,002 |
$ |
675 |
$ |
5,440 |
$ |
5,095 |
Reconciliation of Operating Costs to Consolidated Income Statement Line Items |
|||||||||||||||||||||||||
GAAP operating costs is defined as other operating charges, selling, general and administrative expenses, and research and development expense. The reconciliation below reflects operating costs excluding significant items and non-operating pension/OPEB (benefits) costs. |
|||||||||||||||||||||||||
Three Months Ended |
Three Months Ended |
||||||||||||||||||||||||
As |
Less: |
Less: Non- |
(Non-GAAP) |
As |
Less: |
Less: Non- |
(Non-GAAP) |
||||||||||||||||||
Other operating charges |
$ |
182 |
$ |
— |
$ |
— |
$ |
182 |
$ |
46 |
$ |
(130) |
$ |
— |
$ |
176 |
|||||||||
Selling, general and administrative |
964 |
164 |
(112) |
912 |
1,075 |
10 |
35 |
1,030 |
|||||||||||||||||
Research and development expense |
381 |
— |
(42) |
423 |
483 |
— |
13 |
470 |
|||||||||||||||||
Total |
$ |
1,527 |
$ |
164 |
$ |
(154) |
$ |
1,517 |
$ |
1,604 |
$ |
(120) |
$ |
48 |
$ |
1,676 |
|||||||||
Twelve Months Ended |
Twelve Months Ended |
||||||||||||||||||||||||
As |
Less: |
Less: Non- |
(Non-GAAP) |
As |
Less: |
Less: Non- |
(Non-GAAP) |
||||||||||||||||||
Other operating charges |
$ |
686 |
$ |
(53) |
$ |
— |
$ |
739 |
$ |
459 |
$ |
(286) |
$ |
— |
$ |
745 |
|||||||||
Selling, general and administrative |
4,319 |
386 |
16 |
3,917 |
4,615 |
10 |
150 |
4,455 |
|||||||||||||||||
Research and development expense |
1,641 |
— |
6 |
1,635 |
1,898 |
— |
56 |
1,842 |
|||||||||||||||||
Total |
$ |
6,646 |
$ |
333 |
$ |
22 |
$ |
6,291 |
$ |
6,972 |
$ |
(276) |
$ |
206 |
$ |
7,042 |
Reconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts) |
|||||||||
SCHEDULE D (continued) |
|||||||||
Reconciliation of Operating Earnings Per Share (EPS) Outlook |
|||||||||
The reconciliation below represents the company's outlook on an operating earnings basis, defined as earnings excluding significant items and non-operating pension/OPEB costs. |
|||||||||
Quarter ended |
|||||||||
2017 Outlook |
2016 Actual |
||||||||
EPS from continuing operations (GAAP) |
$ |
1.14 |
$ |
1.39 |
|||||
Significant items (1), (3) |
|||||||||
Transaction costs (3) |
(0.15) |
(0.02) |
|||||||
Gain on sale of entity |
— |
0.24 |
|||||||
Restructuring charges, net |
— |
(0.06) |
|||||||
Customer claims adjustment |
— |
0.02 |
|||||||
Non-operating pension/OPEB costs - estimate |
(0.07) |
(0.05) |
|||||||
Operating EPS (Non-GAAP) |
$ |
1.36 |
$ |
1.26 |
Exchange Gains/Losses on Operating Earnings (1) |
||||||||||||||||
The company routinely uses forward exchange contracts to offset its net exposures, by currency, related to the foreign currency denominated monetary assets and liabilities of its operations. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes. The net pre-tax exchange gains and losses are recorded in other loss, net and the related tax impact is recorded in provision for (benefit from) income taxes on the Consolidated Income Statements. |
||||||||||||||||
Three Months Ended |
Twelve Months Ended |
|||||||||||||||
2016 |
2015 |
2016 |
2015 |
|||||||||||||
Subsidiary Monetary Position Gain (Loss) |
||||||||||||||||
Pre-tax exchange gains (losses) |
$ |
13 |
$ |
(23) |
$ |
198 |
$ |
(320) |
||||||||
Local tax (expenses) benefits |
(97) |
(44) |
(126) |
(70) |
||||||||||||
Net after-tax impact from subsidiary exchange (losses) gains |
$ |
(84) |
$ |
(67) |
$ |
72 |
$ |
(390) |
||||||||
Hedging Program Gain (Loss) |
||||||||||||||||
Pre-tax exchange gains (losses) |
$ |
93 |
$ |
(1) |
$ |
(304) |
$ |
413 |
||||||||
Tax (expenses) benefits |
(33) |
— |
110 |
(150) |
||||||||||||
Net after-tax impact from hedging program exchange gains (losses) |
$ |
60 |
$ |
(1) |
$ |
(194) |
$ |
263 |
||||||||
Total Exchange Gain (Loss) |
||||||||||||||||
Pre-tax exchange gains (losses) (4) |
$ |
106 |
$ |
(24) |
$ |
(106) |
$ |
93 |
||||||||
Tax (expenses) benefits |
(130) |
(44) |
(16) |
(220) |
||||||||||||
Net after-tax exchange losses |
$ |
(24) |
$ |
(68) |
$ |
(122) |
$ |
(127) |
||||||||
As shown above, the "Total Exchange Gain (Loss)" is the sum of the "Subsidiary Monetary Position Gain (Loss)" and the "Hedging Program Gain (Loss)." |
||||||||||||||||
Reconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts) |
||||||||||||||||
SCHEDULE D (continued) |
||||||||||||||||
Reconciliation of Base Income Tax Rate to Effective Income Tax Rate |
||||||||||||||||
Base income tax rate is defined as the effective income tax rate less the effect of exchange gains (losses), as defined above, significant items and non-operating pension/OPEB costs. |
||||||||||||||||
Three Months Ended |
Twelve Months Ended |
|||||||||||||||
2016 |
2015 |
2016 |
2015 |
|||||||||||||
Income (loss) from continuing operations before income taxes (GAAP) |
$ |
353 |
$ |
(421) |
$ |
3,265 |
$ |
2,591 |
||||||||
Add: Significant items - charge (2) |
557 |
622 |
519 |
453 |
||||||||||||
Non-operating pension/OPEB (benefits) costs (1) |
(281) |
86 |
40 |
397 |
||||||||||||
Less: Net exchange gains (losses) (4) |
106 |
(24) |
(106) |
93 |
||||||||||||
Income from continuing operations before income taxes, significant items, exchange gains (losses), and non-operating pension/OPEB costs (Non-GAAP) |
$ |
523 |
$ |
311 |
$ |
3,930 |
$ |
3,348 |
||||||||
Provision for (benefit from) income taxes on continuing operations (GAAP) |
$ |
101 |
$ |
(190) |
$ |
744 |
$ |
696 |
||||||||
Add: Tax benefits on significant items |
173 |
211 |
98 |
105 |
||||||||||||
Tax (expenses) benefits on non-operating pension/OPEB benefits/costs |
(94) |
30 |
19 |
131 |
||||||||||||
Tax expenses on exchange gains/losses |
(130) |
(44) |
(16) |
(220) |
||||||||||||
Provision for income taxes on continuing earnings, excluding exchange gains |
$ |
50 |
$ |
7 |
$ |
845 |
$ |
712 |
||||||||
Effective income tax rate (GAAP) |
28.6 |
% |
45.1 |
% |
22.8 |
% |
26.9 |
% |
||||||||
Significant items and non-operating pension/OPEB costs effect |
— |
% |
(27.3) |
% |
(0.3) |
% |
0.2 |
% |
||||||||
Tax rate, from continuing operations before significant items and non-operating |
28.6 |
% |
17.8 |
% |
22.5 |
% |
27.1 |
% |
||||||||
Exchange gains (losses) effect |
(19.0) |
% |
(15.5) |
% |
(1.0) |
% |
(5.8) |
% |
||||||||
Base income tax rate from continuing operations (Non-GAAP) |
9.6 |
% |
2.3 |
% |
21.5 |
% |
21.3 |
% |
||||||||
(1) |
See Schedule B for detail of significant items. |
||||||||||||||||
(2) |
Fourth quarter 2016 and year to date 2016, non-operating pension/OPEB (benefits) costs include a |
||||||||||||||||
(3) |
The 2017 first quarter outlook for significant items includes the current estimate for first quarter transaction costs associated with the planned merger with The Dow Chemical Company and related activities. It does not include expected gain related to the sale of the company's Nutrition & Health food safety diagnostics business which is expected to close during the first half of 2017 pending customary closing conditions. |
||||||||||||||||
(4) |
Year to date |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dupont-reports-fourth-quarter-and-full-year-results-300395253.html
SOURCE
Governor Cuomo Announces Decisive Actions to Secure Access to Reproductive Health Services in New York
Repeal of Medicaid expansion could worsen Pennsylvania budget, state officials say
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News